Needham & Company Reiterates Buy Rating, $8 PT on Trevi Therapeutics (TRVI) Ahead of PRISM Trial Readout

Needham & Company analyst Serge Belanger reiterated a Buy rating and $8.00 price target on Trevi Therapeutics (NASDAQ: TRVI), following the company's Q4 report.

The analyst quotes: "TRVI reported 4Q21 financials and provided a corporate update. The co. recently made headlines when it reported positive interim results from its ph 2 proof-of-concept CANAL trial where Haduvio demonstrated strong consistent cough frequency reductions in IPF patients. TRVI plans to advance the IPF cough program to a ph 2b trial and explore the potential of Haduvio in broader cough indications. Despite CANAL trial success, the main near-term catalyst for TRVI remains the ph 2b/3 PRISM trial evaluating Haduvio for prurigo nodularis (PN). Top-line readout is expected in late 2Q22. We maintain our Buy rating and $8PT ahead of the PRISM trial readout, based on a discounted valuation (that reflects current cash level) and the opportunity for Haduvio to address two significant indications (PN and IPF cough) with significant unmet needs."

For an analyst ratings summary and ratings history on Trevi Therapeutics click here. For more ratings news on Trevi Therapeutics click here.

Shares of Trevi Therapeutics closed at $1.53 yesterday.

By Vlad Schepkov | [email protected]

You May Also Be Interested In

• Coherent (COHR) PT Raised to $420 at Needham
• Needham Reiterates Buy Rating on Harmonic Inc. (HLIT)
• Needham Reiterates Buy Rating on WhiteFiber Inc (WYFI)